Michael Tilson, MD
Family Medicine · Monroe, MINPI 1801242334
Payments from drug & device makers
Across 195 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$615
- Lilly USA, LLC$442
- Pfizer$405
- AbbVie$287
- Amgen$262
- Exact Sciences$158
- plus $864 from 18 others
What the payments were for
- Food & beverage$3,017100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $615 |
| Lilly USA, LLC | 34 | $442 |
| Pfizer | 27 | $405 |
| AbbVie | 12 | $287 |
| Amgen | 18 | $262 |
| Exact Sciences | 7 | $158 |
| GSK | 7 | $111 |
| AstraZeneca | 6 | $105 |
| Boehringer Ingelheim | 5 | $83 |
| Merck | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Antares Pharma, Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| Novartis | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Mylan Pharmaceuticals Inc. | 1 | $21 |
| Bioventus LLC | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
How this compares
$3,032 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 174 | $227,693 |
| OzempicSemaglutide | 91 | $127,252 |
| EliquisApixaban | 105 | $106,767 |
| JanuviaSitagliptin Phosphate | 74 | $84,651 |
| JanumetSitagliptin Phos/Metformin Hcl | 47 | $67,599 |
| FarxigaDapagliflozin Propanediol | 67 | $46,462 |
| MounjaroTirzepatide | 30 | $38,657 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $35,685 |
| Repatha SureclickEvolocumab | 33 | $32,039 |
| Bydureon BciseExenatide Microspheres | 15 | $31,534 |
| InvokanaCanagliflozin | 26 | $29,432 |
| TrintellixVortioxetine Hydrobromide | 19 | $24,356 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $21,944 |
| TrulicityDulaglutide | 16 | $20,164 |
| Atorvastatin Calcium | 1,252 | $19,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $83 | $259,659209 claims |
| MerckJanuvia, Janumet, Janumet Xr | $75 | $170,140144 claims |
| Novo NordiskOzempic | $615 | $127,25291 claims |
| PfizerEliquis, Paxlovid | $405 | $112,131119 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $111 | $62,11758 claims |
| Lilly USA, LLCMounjaro, Trulicity | $442 | $58,82146 claims |
| AstraZenecaFarxiga, Symbicort | $105 | $53,47378 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $73 | $24,35619 claims |
| AbbVieSynthroid | $287 | $4,02958 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Monroe
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.